Guidelines and Tools to Improve Clinical NGS Testing
About This Webcast
Join us for an insightful session about NGS testing guidelines and tools. Next-Generation Sequencing (NGS) testing has transformed molecular diagnostics. Adhering to rigorous standards is crucial for accurate, reliable results. Using the College of American Pathologists (CAP) guidelines, participants will gain valuable insights into essential aspects, such as assay validation and proficiency testing/external quality assessment (PT/EQA) programs. This complete education on clinical NGS testing also includes identification and correction of common molecular testing errors. Join us to enhance your understanding of best practices, improving the reliability and accuracy of molecular diagnostics in your clinical setting. Connect with Ravindra Kolhe, MD, PhD, FCAP in this 60-minute session as he brings his insight and knowledge. Following the presentation, there will be time to answer submitted questions. Webinar objectives: Learn CAP guidelines for clinical NGS testing, including validation. Recognize the importance of PT/EQA programs for accurate NGS results. Identify and address common errors in clinical NGS testing and explore corrective strategies. This is one of two identical sessions presented for the convenience of our worldwide audience. CLICK HERE TO SEE LOCAL TIME FOR THIS SESSION Option 1 will be presented 12 hours earlier than this one. If you prefer that time, please visit https://bit.ly/capimd319a
Speakers
Ravindra Kolhe, MD, PhD, FCAP
Professor and Interim Chair of Pathology , Associate Dean for Translational Research, Medical College of Georgia
Dr. Ravindra Kolhe is a Professor and Leon Henri Charbonnier Endowed Chair in Pathology at Augusta University and is the inaugural Associate Dean for translational research at the Medical College of Georgia. He also serves as the Associate Cancer Center Director for Genomics at the Georgia Cancer Center. Dr. Kolhe currently leads an NCI-designated translational pathology laboratory for MATCH testing, which focuses on comprehensive genomic testing in oncology. He co-founded a consortium (SEQUOIA) of 40+ clinical laboratories across the globe for the democratization of NGS testing in oncology & successfully helped multiple labs to bring NGS testing in-house. He served on the Georgia Governor’s Task Force for COVID-19 and successfully led the COVID-19 screening program for the State of Georgia during the early Pandemic. Dr. Kolhe is also a co-founder of a COVID-19 Host Genome Structural Variation Consortium and coordinated a global network of researchers who are contributing to our collective knowledge on host genome response to the SARS-CoV-2 infection and COVID-19 disease. He has led several studies focused on adapting and validating newer technologies (NGS, RNA-seq, OGM, etc.) in CLIA laboratories by establishing PLA & Z-codes and reimbursement. He has authored more than 100+ peer-reviewed publications and serves on multiple CAP committees and scientific advisory boards for numerous profit and non-profit organizations. Dr. Kolhe received his medical degree from Mahatma Gandhi Mission’s Medical College, Aurangabad, India. He completed his Ph.D. in Biology at Mississippi University. He completed his residency in pathology at the Medical College of Georgia, Augusta, and his Fellowship in Molecular and Genetic Pathology at Emory University.